No Data
No Data
Asia Pacific Pharmaceutical (002370.SZ): Net loss of 2.9984 million yuan in the first quarter
Gelonghui, April 26 | Asia Pacific Pharmaceutical (002370.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 113 million yuan, down 8.80% from the previous year; net profit attributable to shareholders of listed companies - RMB 29.984 million; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - RMB 2,211,300; and basic earnings per share - 0.0049 yuan.
Asia Pacific Pharmaceutical (002370.SZ) reported 2023 annual results, with a net loss of 11.877 million yuan, which narrowed the year-on-year loss
Asia Pacific Pharmaceutical (002370.SZ) released its 2023 annual report. The company achieved operating income of 4 during the reporting period...
Asia Pacific Pharmaceutical (002370.SZ): 3 products collected in the country (injectable omeprazole sodium, injectable cefumezole sodium, cefixime capsules)
Gelonghui, Feb. 29 | Asia Pacific Pharmaceutical (002370.SZ) said on the investor interactive platform that the company has entered the national collection of 3 products (injectable omeprazole sodium, injectable cefamezole sodium, cefixime capsules).
Asia Pacific Pharmaceutical (002370.SZ): No drugs to treat nuclear contamination
Gelonghui, Feb. 21丨An investor asked Asia Pacific Pharmaceutical (002370.SZ) on the investor interactive platform, “Are your company's drugs aimed at treating nuclear pollution?” The company replied that the company has no drugs to treat nuclear contamination.
Fubon Group, the controlling shareholder of Asia Pacific Pharmaceutical (002370.SZ), increased 1.67% of the company's shares
According to Zhitong Finance App, Asia Pacific Pharmaceutical (002370.SZ) issued an announcement. On February 7, 2024, the company received a notice from the controlling shareholder Fubon Group. From February 6, 2024 to February 7, 2024, Fubon Group increased its holdings of the company's shares by 10.17 million shares through centralized bidding transactions through the Shenzhen Stock Exchange system, accounting for 1.67% of the company's total share capital.
Express News | Asia Pacific Pharmaceutical: Due to job adjustments, Huang Xiaoming applied to resign as general manager of the company
No Data